$2.13
-0.04 (-1.62%)
Open$2.15
Previous Close$2.17
Day High$2.19
Day Low$2.09
52W High$4.34
52W Low$1.48
Volume—
Avg Volume578.9K
Market Cap94.49M
P/E Ratio—
EPS$-0.60
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,310.8% upside
Current
$2.13
$2.13
Target
$30.05
$30.05
$22.12
$30.05 avg
$38.96
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 11.43M | 10.74M | 10.31M |
| Net Income | -2,402,162 | -1,945,366 | -2,138,218 |
| Profit Margin | -21.0% | -18.1% | -20.7% |
| EBITDA | -3,961,862 | -3,629,854 | -3,514,676 |
| Free Cash Flow | -2,281,552 | -2,429,555 | -1,597,015 |
| Rev Growth | +22.4% | -6.0% | +21.1% |
| Debt/Equity | 1.10 | 1.30 | 1.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |